CompletedPhase 3NCT02053792
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Program DirectorCSL Behring
- Intervention
- rIX-FP(biological)
- Enrollment
- 97 enrolled
- Eligibility
- 70 years · MALE
- Timeline
- 2014 – 2021
Study locations (30)
- University of Colorado, Aurora, Colorado, United States
- Indiana Hemophilia & Thrombosis Center Inc., Indianapolis, Indiana, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Royal Children's Hospital, Parkville, Victoria, Australia
- The Children's Hospital Westmead, Westmead, Victoria, Australia
- Department of Pediatrics, Medical University of Vienna, Vienna, Austria
- Medical University of Vienna, Vienna General Hospital, Vienna, Austria
- SHAT "Joan Pavel" ODD [Hemorrhagic Diathesis & Anemia], Sofia, Bulgaria
- McMaster University, Hamilton, Ontario, Canada
- Fakultni nemocnice Brno, Brno, Czechia
- Fakultni Nemocrice Ostrava, Ostrava-Poruba, Czechia
- Fakultni nemocnice v Motole, Prague, Czechia
- CHRU Hopital Morvan, Brest, France
- Hopital Louis Pradel, Bron, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02053792 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.